165 results on '"McKone E"'
Search Results
2. 166 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
3. 156 Multicenter validation of the CF-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
4. 170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study
5. 251 Evaluation of the Medication Electronic Monitoring Systems n adherence measurement in a real-world setting
6. 185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
7. P043 Significant reduction in abdominal symptoms assessed with the CFAbd-Score over 6 months of elexacaftor/tezacaftor/ivacaftor (ETI) - follow-up results from Irish and British cystic fibrosis patients (RECOVER study)
8. ePS6.10 A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis
9. WS06.02 Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in people with cystic fibrosis in a real-world setting – the RECOVER study
10. 564: Impact of elexacaftor/tezacaftor/ivacaftor treatment on clinical outcomes in people with CF in a real-world setting—The RECOVER trial
11. 565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study
12. P042 RECOVER - the Real World Clinical Outcomes with Novel Modulator therapy combinations in people with cystic fibrosis
13. P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study
14. P156 Mycobacterium abscessus treatment in adult patients with cystic fibrosis: case series and review
15. P071 Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centre's perspective
16. P102 Mycobacterium abscessus treatment complexity in adult patients with cystic fibrosis: case series and review
17. ePS3.02 Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
18. P267 An evaluation of the nutritional status of Irish adults attending the National Referral Centre for Adult Cystic Fibrosis in 2019
19. Do people have insight into their face recognition abilities?
20. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele
21. P113 Treatment of adult cystic fibrosis patients with ceftolozanetazobactam with a previous adverse drug reaction to piperacillintazobactam
22. P176 Detection of respiratory viruses in cystic fibrosis: comparison of nasal FLOQ Swabs™ and sputum using the FilmArray® platform
23. P066 Disease progression and burden in patients with cystic fibrosis homozygous for F508del across Europe in an observational registry (VOICE Study)
24. P208 Impact of ivacaftor treatment disruption on clinical outcomes: a single centre study
25. P023 Impact of lumacaftor/ivacaftor (Orkambi®) on proton pump inhibitor use in adult cystic fibrosis patients
26. Subjective self-assessment of face recognition ability is only weakly related to objective measures of face recognition performance
27. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
28. ePS03.4 Improved rate of decline in percent predicted FEV 1 (ppFEV 1 ) is not associated with acute improvement in ppFEV 1 in patients with cystic fibrosis (CF) treated with ivacaftor
29. WS02.4 Short-term and long-term effects of ivacaftor treatment on sputum microbiota in people with the G551D CFTR mutation
30. WS18.5 Direct medical cost of CF care in the Irish public healthcare system
31. WS3.1 The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation
32. WS5.4 Can registry data be used to examine cystic fibrosis (CF) health service utilisation? Perspectives of the Irish CF Registry
33. WS7.4 Inhaled aztreonam lysine (Cayston) therapy significantly improves lung function, weight, hospitalisations and excerbation rates prospectively – an Irish and UK real world experience
34. A new theoretical approach to improving face recognition in disorders of central vision: Face caricaturing
35. Importance of the inverted control in measuring holistic face processing with the composite effect and part-whole effect.
36. Aftereffects support opponent coding of face gender
37. ePS03.4 Improved rate of decline in percent predicted FEV1 (ppFEV1) is not associated with acute improvement in ppFEV1 in patients with cystic fibrosis (CF) treated with ivacaftor
38. Caricaturing improves face recognition in simulated age-related macular degeneration.
39. Look out! Gaze-cueing is greater from fearful faces in a dangerous context for children and adults
40. Reducing the other-race effect requires childhood visual experience, not increased social motivation
41. Individual differences in the ability to recognize facial expressions are associated with the strength of adaptive expression coding but not the strength of holistic expression coding.
42. Subjective self-assessment of face recognition ability is only weakly related to objective measures of face recognition performance
43. Global face distortion aftereffects tap face-specific and shape-generic processes
44. WS6.4 Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR Mutation
45. 213 Study evaluating the effect of weekends on activity and inflammatory markers in adult patients with cystic fibrosis
46. 250 Vitamin D deficiency and thoracic kyphosis in adult cystic fibrosis patients
47. WS19.2 Development and application of quality improvement questionnaire in adults with cystic fibrosis
48. 295 Pregnancy outcomes in female cystic fibrosis patients attending an adult CF center
49. Internal feature position in faces is coded relative to external contour: adaptation aftereffects, neural coding models, and 3D head rotation
50. Do face adaptation aftereffects predict face recognition? Evidence from individual differences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.